Pulmonary large cell neuroendocrine carcinoma (LCNEC): a population-based study addressing recent molecular-genetic advances and emerging therapeutic approaches.
High-grade neuroendocrine
Large cell neuroendocrine carcinoma
Lung cancer
Molecular
Primary pulmonary
Small cell
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
07
02
2023
accepted:
05
04
2023
medline:
2
11
2023
pubmed:
16
4
2023
entrez:
15
4
2023
Statut:
ppublish
Résumé
Large cell neuroendocrine carcinoma (LCNEC) of the lung is a rare, aggressive cancer most commonly found in the lungs but not exclusively, with a worse prognosis than non-small cell lung carcinomas. Currently, LCNEC patients are treated using small cell and non-small cell protocols. This study aims to use the SEER database to identify demographic, clinical, pathological, and therapeutic factors affecting the prognosis and survival of patients with LCNEC of the lung. Demographic, clinical, and management data of patients with lung LCNEC were extracted from the SEER database for the period 2000-2018. In the USA, LCNEC has a higher incidence in elderly white men: M:F ratio = 1.2:1, Caucasian: 83.3%, mean age: 67 ± 10.2 years. The most common treatment modality was chemotherapy only: 29.2%, followed by surgery: 21.5% (but in this group the statuses of chemotherapy were unknown), and combination surgery/chemotherapy: 8.8%. The overall and cause-specific 5-year survival was 17.5% (95% CI 16.3-18.8) and 21.9% (95% CI 20.5-23.4), respectively. By treatment, the best 5-year survival was for surgery alone (48%), followed by multimodality therapy (chemo + surgery + radiation) at 35% (95% CI 27-43). Age > 60 years, male gender, size > 7 cm, and nodal and liver metastasis were independent risk factors associated with increased mortality. Lung LCNEC is an aggressive neoplasm most common in older white males that presents at an advanced stage despite small primary tumors. Most patients die within 2 years. The best predictor of survival is surgery with chemotherapy. Given its dismal prognosis, new treatment guidelines are needed for this aggressive cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Large cell neuroendocrine carcinoma (LCNEC) of the lung is a rare, aggressive cancer most commonly found in the lungs but not exclusively, with a worse prognosis than non-small cell lung carcinomas. Currently, LCNEC patients are treated using small cell and non-small cell protocols. This study aims to use the SEER database to identify demographic, clinical, pathological, and therapeutic factors affecting the prognosis and survival of patients with LCNEC of the lung.
METHODS
METHODS
Demographic, clinical, and management data of patients with lung LCNEC were extracted from the SEER database for the period 2000-2018.
RESULTS
RESULTS
In the USA, LCNEC has a higher incidence in elderly white men: M:F ratio = 1.2:1, Caucasian: 83.3%, mean age: 67 ± 10.2 years. The most common treatment modality was chemotherapy only: 29.2%, followed by surgery: 21.5% (but in this group the statuses of chemotherapy were unknown), and combination surgery/chemotherapy: 8.8%. The overall and cause-specific 5-year survival was 17.5% (95% CI 16.3-18.8) and 21.9% (95% CI 20.5-23.4), respectively. By treatment, the best 5-year survival was for surgery alone (48%), followed by multimodality therapy (chemo + surgery + radiation) at 35% (95% CI 27-43). Age > 60 years, male gender, size > 7 cm, and nodal and liver metastasis were independent risk factors associated with increased mortality.
CONCLUSION
CONCLUSIONS
Lung LCNEC is an aggressive neoplasm most common in older white males that presents at an advanced stage despite small primary tumors. Most patients die within 2 years. The best predictor of survival is surgery with chemotherapy. Given its dismal prognosis, new treatment guidelines are needed for this aggressive cancer.
Identifiants
pubmed: 37060529
doi: 10.1007/s10238-023-01071-8
pii: 10.1007/s10238-023-01071-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3947-3955Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15(6):529–53.
doi: 10.1097/00000478-199106000-00003
pubmed: 1709558
Corbett V, Arnold S, Anthony L, Chauhan A. Management of large cell neuroendocrine carcinoma. Front Oncol. 2021;11:653162. https://doi.org/10.3389/fonc.2021.653162 .
doi: 10.3389/fonc.2021.653162
pubmed: 34513663
pmcid: 8432609
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.
doi: 10.1097/JTO.0000000000000630
pubmed: 26291008
Fernandez FG, Battafarano RJ. Large-cell neuroendocrine carcinoma of the lung: an aggressive neuroendocrine lung cancer. Semin Thorac Cardiovasc Surg. 2006;18(3):206–10.
doi: 10.1053/j.semtcvs.2006.08.007
pubmed: 17185180
Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K, Iizasa T, Kimura H, Nakatani Y, Fujisawa T. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 2006;82(5):1802–7. https://doi.org/10.1016/j.athoracsur.2006.05.109 .
doi: 10.1016/j.athoracsur.2006.05.109
pubmed: 17062251
Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322:764–74.
doi: 10.1001/jama.2019.11058
pubmed: 31454018
Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24(1):70–6.
doi: 10.1200/JCO.2005.04.1202
pubmed: 16382115
Fasano M, della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma from epidemiology to therapy. J Thorac Oncol. 2015;10:1133–41. https://doi.org/10.1097/JTO.0000000000000589 .
doi: 10.1097/JTO.0000000000000589
pubmed: 26039012
pmcid: 4503246
Travis WDBE, Burke AP, Marx A, Nicholson AGL. WHO classification of tumours of the lung, pleura, thymus and heart (medicine), 4th edn. WHO Classification of Tumours Editorial Board: World Health Organization; 2015.
Le Treut J, et al. Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013;24(6):1548–52.
doi: 10.1093/annonc/mdt009
pubmed: 23406729
Zou L, Guo T, Ye L, Zhou Y, Chu L, Chu X, et al. Outcomes for surgery in stage IA large cell lung neuroendocrine compared with other types of non-small cell lung cancer: a propensity score matching study based on the surveillance, epidemiology, and end results (SEER) database. Front Oncol. 2020;10:572462.
doi: 10.3389/fonc.2020.572462
pubmed: 33324549
pmcid: 7727448
Derks JL, Hendriks LE, Buikhuisen WA, Groen HJ, Thunnissen E, van Suylen RJ, et al. Clinical features of large cell neuroendocrine carcinoma: a population-based overview. Eur Respir J. 2016;47(2):615–24.
doi: 10.1183/13993003.00618-2015
pubmed: 26541538
Park MS, Kim KD, Chung JH, Shin DH, Chung KY, Kim JH, et al. Clinical features of pulmonary large cell neuroendocrine carcinoma. Cancer Res Treat. 2003;35(3):245–53.
doi: 10.4143/crt.2003.35.3.245
pubmed: 26680943
Zacharias J, Nicholson AG, Ladas GP, Goldstraw P. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg. 2003;75(2):348–52.
doi: 10.1016/S0003-4975(02)04118-8
pubmed: 12607637
Kujtan L, Muthukumar V, Kennedy KF, Davis JR, Masood A, Subramanian J. The role of systemic therapy in the management of stage I large cell neuroendocrine carcinoma of the lung. J Thorac Oncol. 2018;13(5):707–14.
doi: 10.1016/j.jtho.2018.01.019
pubmed: 29391287
Kenmotsu H, Niho S, Tsuboi M, Wakabayashi M, Ishii G, Nakagawa K, et al. Randomized phase III study of irinotecan plus cisplatin versus etoposide plus cisplatin for completely resected high-grade neuroendocrine carcinoma of the lung: JCOG1205/1206. J Clin Oncol. 2020;38(36):4292–301.
doi: 10.1200/JCO.20.01806
pubmed: 33136471
Jiang Y, Lei C, Zhang X, Cui Y, Che K, Shen H. Double-edged role of radiotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Cancer. 2019;10(25):6422–30.
doi: 10.7150/jca.32446
pubmed: 31772675
pmcid: 6856741
Gu J, Gong D, Wang Y, Chi B, Zhang J, Hu S, et al. The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung. Cancer Med. 2019;8(6):2979–93.
doi: 10.1002/cam4.2188
pubmed: 31087628
pmcid: 6558599
Bunn HN Jr, Langer PA, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–43. https://doi.org/10.1200/JCO.2005.04.8595 .
doi: 10.1200/JCO.2005.04.8595
pubmed: 16648503
Derks JL, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, Groen HJM, Smit EF, Damhuis R, van den Broek EC, Charbrier A, Foll M, McKay JD, Fernandez-Cuesta L, Speel E-JM, Dingemans A-MC, PALGA-Group. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24(1):33–42. https://doi.org/10.1158/1078-0432.CCR-17-1921 .
doi: 10.1158/1078-0432.CCR-17-1921
pubmed: 29066508
Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas HA, Chang L, Gong Y, Wu N, Zhong J, Chen W, Chen H, Dong Z, Zhu X, Li J, Wang Y, An T, Wu M, Wang Z, Wang J, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Lee JJ, Heymach JV, Wistuba II, Kalhor N, Yang L, Yi X, Futreal PA, Glisson BS, Xia X, Zhang J, Zhao J. The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma. Clin Cancer Res. 2020;26(4):892–901. https://doi.org/10.1158/1078-0432.CCR-19-0556 .
doi: 10.1158/1078-0432.CCR-19-0556
pubmed: 31694833
Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors. Clin Cancer Res. 2020;26(10):2290–6. https://doi.org/10.1158/1078-0432.CCR-19-3356 .
doi: 10.1158/1078-0432.CCR-19-3356
pubmed: 31969335
pmcid: 7231627
Fournel L, Falcoz PE, Alifano M, Charpentier MC, Boudaya MS, Magdeleinat P, et al. Surgical management of pulmonary large cell neuroendocrine carcinomas: a 10-year experience. Eur J Cardiothorac Surg. 2013;43(1):111–4.
doi: 10.1093/ejcts/ezs174
pubmed: 22529187
Saji H, Tsuboi M, Matsubayashi J, Miyajima K, Shimada Y, Imai K, et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs. 2010;21(1):89–93.
doi: 10.1097/CAD.0b013e328330fd79
pubmed: 19770636
Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, et al. The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma. Clin Cancer Res. 2020;26:892–901.
doi: 10.1158/1078-0432.CCR-19-0556
pubmed: 31694833
George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun. 2018;9(1):1048.
doi: 10.1038/s41467-018-03099-x
pubmed: 29535388
pmcid: 5849599
Derks JL, Leblay N, Thunnissen E, Van Suylen RJ, Den Bakker M, Groen HJM, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24(1):33–42.
doi: 10.1158/1078-0432.CCR-17-1921
pubmed: 29066508
Hermans BCM, Derks JL, Thunnissen E, van Suylen RJ, den Bakker MA, Groen HJM, et al. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). Lung Cancer. 2019;130:179–86.
doi: 10.1016/j.lungcan.2019.02.022
pubmed: 30885341
Kim C, McGrath JE, Xiu J, Nagasaka M, Ma PC, Nieva JJ, et al. Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2021;39(15_suppl):8535.
doi: 10.1200/JCO.2021.39.15_suppl.8535
Ferrara MG, Stefani A, Simbolo M, Pilotto S, Martini M, Lococo F, et al. Large cell neuro-endocrine carcinoma of the lung: current treatment options and potential future opportunities. Front Oncol. 2021;11:650293.
doi: 10.3389/fonc.2021.650293
pubmed: 33937057
pmcid: 8081906
Atieh T, Huang CH. Treatment of advanced-stage large cell neuroendocrine cancer (LCNEC) of the lung: a tale of two diseases. Front Oncol. 2021;11:667468.
doi: 10.3389/fonc.2021.667468
pubmed: 34178652
pmcid: 8226095
Popper H, Brcic L. Diagnosis and molecular profiles of large cell neuroendocrine carcinoma with potential targets for therapy. Front Oncol. 2021;11:655752.
doi: 10.3389/fonc.2021.655752
pubmed: 34307132
pmcid: 8293294
May MS, Kinslow CJ, Adams C, Saqi A, Shu CA, Chaudhary KR, Wang TJC, Cheng SK. Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States. Transl Lung Cancer Res. 2021;10(1):71–9. https://doi.org/10.21037/tlcr-20-374 .
doi: 10.21037/tlcr-20-374
pubmed: 33569294
pmcid: 7867769
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV, IMpower133 Study Group. First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9. https://doi.org/10.1056/NEJMoa1809064 .
doi: 10.1056/NEJMoa1809064
pubmed: 30280641
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L, CASPIAN Investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51–65. https://doi.org/10.1016/S1470-2045(20)30539-8 .
doi: 10.1016/S1470-2045(20)30539-8
pubmed: 33285097
Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3488–515.
doi: 10.1200/JCO.2015.62.1342
pubmed: 26324367
pmcid: 5019421